NRIX ▼ -1.2% - Nurix Therapeutics, Inc.
$NRIX - Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
07-OCT-2026 01:00 AM ET
Share this post
More filings for $NRIX
NRIX ▼ -0.2% - Nurix Therapeutics, Inc.Oct 5, 2026NRIX ▲ +0.0% - Nurix Therapeutics, Inc.Sep 29, 2026NRIX - Nurix Therapeutics, Inc. - SEC Filing Update (23-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 23, 2026NRIX - Nurix Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026NRIX - Nurix Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$NRIX SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $NRIX filing history →💬 Comments
Loading comments…
Leave a comment